Unimedic Pharma acquires XGX Pharma

Unimedic Pharma AB has now completed the acquisition of XGX Pharma ApS (“XGX”) in Denmark.

XGX is a fast-growing specialty pharma company with a pipeline of new products. Currently, XGX has eight products on the market, primarily in the Nordics. The pipeline consists of niche products either in late-stage development or registration phase.

Johan Frödin, CEO of Unimedic Group, comments the acquisition:” We are thrilled to welcome XGX to the Unimedic group. The acquisition aligns with our long-term strategy to become a leading specialty pharma company in the Nordics and enables us to support more patients across a wider range of therapeutic areas. I am truly impressed by the founders, Jens-Nikolaj Schøier (CEO) and Dr. Sohail Asghar (COO), and how they have built XGX, and I look forward to working together with them and their team”.

The acquisition of XGX positions Unimedic Pharma as one of the leading Nordic specialty pharma companies with a broad portfolio of niche products. Many of the pipeline products are own products. Together with the existing own products, Unimedic Pharma can offer attractive out-licensing opportunities beyond the Nordic region.

Jens-Nikolaj Schøier, CEO of XGX, comments the transaction: "We are proud of the strong momentum XGX has built as a fast-expanding specialty pharma company. Joining forces with Unimedic Pharma is a natural next step in our journey. Together, our combined footprint in the Nordics becomes significantly stronger, and we are well positioned to expand beyond the region. We are excited to become part of the Unimedic and MedCap family and look forward to working together to bring more value to patients and partners across a broader geographic scope."

About Unimedic Pharma AB

Unimedic Pharma is a fully integrated Swedish specialty pharma company with extensive experience in marketing, sales, and drug development. Unimedic Pharma partner with pharmaceutical companies for in- and out-licensing of niche and original pharmaceuticals in the Nordic and international markets. Learn more at www.unimedicpharma.se.

For more information, contact:

Johan Frödin, CEO, Phone +46 (0)70 878 72 80, Email johan.frodin@unimedic.se